By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vectura Group plc 

1 Prospect West

Chippenham  Wiltshire  SN14 6FH  United Kingdom
Phone: 44-0-1249-667700 Fax: 44-0-1249-667701



Company News
Vectura Group plc (VEC.L) Release: FLAME Study Shows Superiority Of Novartis AG (NVS)’ Ultibro Breezhaler Over Seretide In Reducing COPD Exacerbations 11/17/2015 10:29:27 AM
Vectura Group plc (VEC.L) Release: Strong Interim Results Driven By 67% Increase In Royalties 11/17/2015 10:14:12 AM
Vectura Group plc (VEC.L) Release: VR632 EU Development Milestone 10/30/2015 10:33:32 AM
Vectura Group plc (VEC.L) to Shutter Site in Germany 4/14/2015 9:58:45 AM
Vectura Group plc (VEC.L) Release: Appointment Of Non-Executive Director 4/1/2015 9:18:29 AM
Vectura Group plc (VEC.L) Release: AirFluSal Forspiro Launched In Portugal And Ireland 3/11/2015 10:43:37 AM
Vectura Group plc (VEC.L) Announces Chief Executive’s Intention To Step Down 2/3/2015 9:56:40 AM
Vectura Group plc (VEC.L) Release: Submission Of Regulatory Applications To U.S. FDA And Robust Phase 3 Results For QVA149 And NVA237 1/8/2015 9:40:31 AM
Vectura Group plc (VEC.L) Signs Global Development And Licence Agreement With Janssen Biotech Inc. (JNJ) In Asthma/COPD 1/6/2015 8:55:22 AM
Vectura Group plc (VEC.L)’s Investigational Drug/Device Combination VR475 Met Primary Endpoint And Has Shown Significant Clinical Benefit In A Phase 2b/3 Trial In Severe Asthma Patients 12/11/2014 6:35:04 AM